Cargando…

Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA

Pulmonary arterial hypertension (PAH) is characterized by remodeling of the pulmonary arteries, and defined by elevated pulmonary arterial pressure, measured during right heart catheterization. There are three main challenges to the diagnostic and therapeutic process of patients with PAH. First, it...

Descripción completa

Detalles Bibliográficos
Autores principales: Rogula, Sylwester, Pomirski, Bartosz, Czyżak, Norbert, Eyileten, Ceren, Postuła, Marek, Szarpak, Łukasz, Filipiak, Krzysztof J., Kurzyna, Marcin, Jaguszewski, Miłosz, Mazurek, Tomasz, Grabowski, Marcin, Gąsecka, Aleksandra
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582157/
https://www.ncbi.nlm.nih.gov/pubmed/36277769
http://dx.doi.org/10.3389/fcvm.2022.980718
_version_ 1784812773658591232
author Rogula, Sylwester
Pomirski, Bartosz
Czyżak, Norbert
Eyileten, Ceren
Postuła, Marek
Szarpak, Łukasz
Filipiak, Krzysztof J.
Kurzyna, Marcin
Jaguszewski, Miłosz
Mazurek, Tomasz
Grabowski, Marcin
Gąsecka, Aleksandra
author_facet Rogula, Sylwester
Pomirski, Bartosz
Czyżak, Norbert
Eyileten, Ceren
Postuła, Marek
Szarpak, Łukasz
Filipiak, Krzysztof J.
Kurzyna, Marcin
Jaguszewski, Miłosz
Mazurek, Tomasz
Grabowski, Marcin
Gąsecka, Aleksandra
author_sort Rogula, Sylwester
collection PubMed
description Pulmonary arterial hypertension (PAH) is characterized by remodeling of the pulmonary arteries, and defined by elevated pulmonary arterial pressure, measured during right heart catheterization. There are three main challenges to the diagnostic and therapeutic process of patients with PAH. First, it is difficult to differentiate particular PAH etiology. Second, invasive diagnostic is required to precisely determine the severity of PAH, and thus to qualify patients for an appropriate treatment. Third, the results of treatment of PAH are unpredictable and remain unsatisfactory. MicroRNAs (miRNAs) are small non-coding RNAs that regulate post transcriptional gene-expression. Their role as a prognostic, and diagnostic biomarkers in many different diseases have been studied in recent years. MiRNAs are promising novel biomarkers in PAH due to their activity in various molecular pathways and processes underlying PAH. Lack of biomarkers to differentiate between particular PAH etiology and evaluate the severity of PAH, as well as paucity of therapeutic targets in PAH open a new field for the possibility to use miRNAs in these applications. In our article, we discuss the potential of miRNAs use as diagnostic tools, prognostic biomarkers and therapeutic targets in PAH.
format Online
Article
Text
id pubmed-9582157
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-95821572022-10-21 Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA Rogula, Sylwester Pomirski, Bartosz Czyżak, Norbert Eyileten, Ceren Postuła, Marek Szarpak, Łukasz Filipiak, Krzysztof J. Kurzyna, Marcin Jaguszewski, Miłosz Mazurek, Tomasz Grabowski, Marcin Gąsecka, Aleksandra Front Cardiovasc Med Cardiovascular Medicine Pulmonary arterial hypertension (PAH) is characterized by remodeling of the pulmonary arteries, and defined by elevated pulmonary arterial pressure, measured during right heart catheterization. There are three main challenges to the diagnostic and therapeutic process of patients with PAH. First, it is difficult to differentiate particular PAH etiology. Second, invasive diagnostic is required to precisely determine the severity of PAH, and thus to qualify patients for an appropriate treatment. Third, the results of treatment of PAH are unpredictable and remain unsatisfactory. MicroRNAs (miRNAs) are small non-coding RNAs that regulate post transcriptional gene-expression. Their role as a prognostic, and diagnostic biomarkers in many different diseases have been studied in recent years. MiRNAs are promising novel biomarkers in PAH due to their activity in various molecular pathways and processes underlying PAH. Lack of biomarkers to differentiate between particular PAH etiology and evaluate the severity of PAH, as well as paucity of therapeutic targets in PAH open a new field for the possibility to use miRNAs in these applications. In our article, we discuss the potential of miRNAs use as diagnostic tools, prognostic biomarkers and therapeutic targets in PAH. Frontiers Media S.A. 2022-10-06 /pmc/articles/PMC9582157/ /pubmed/36277769 http://dx.doi.org/10.3389/fcvm.2022.980718 Text en Copyright © 2022 Rogula, Pomirski, Czyżak, Eyileten, Postuła, Szarpak, Filipiak, Kurzyna, Jaguszewski, Mazurek, Grabowski and Gąsecka. https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cardiovascular Medicine
Rogula, Sylwester
Pomirski, Bartosz
Czyżak, Norbert
Eyileten, Ceren
Postuła, Marek
Szarpak, Łukasz
Filipiak, Krzysztof J.
Kurzyna, Marcin
Jaguszewski, Miłosz
Mazurek, Tomasz
Grabowski, Marcin
Gąsecka, Aleksandra
Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
title Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
title_full Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
title_fullStr Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
title_full_unstemmed Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
title_short Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA
title_sort biomarker-based approach to determine etiology and severity of pulmonary hypertension: focus on microrna
topic Cardiovascular Medicine
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9582157/
https://www.ncbi.nlm.nih.gov/pubmed/36277769
http://dx.doi.org/10.3389/fcvm.2022.980718
work_keys_str_mv AT rogulasylwester biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT pomirskibartosz biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT czyzaknorbert biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT eyiletenceren biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT postułamarek biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT szarpakłukasz biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT filipiakkrzysztofj biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT kurzynamarcin biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT jaguszewskimiłosz biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT mazurektomasz biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT grabowskimarcin biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna
AT gaseckaaleksandra biomarkerbasedapproachtodetermineetiologyandseverityofpulmonaryhypertensionfocusonmicrorna